natgillin/translations-raw huggingface dataset:
A genic expression adenoviral hybrid vector according to claim 1, wherein element iii is a tumor specific promoter having a sequence selected from SEQ ID No 7, corresponding to AFP p+e, and SEQ ID No 15, corresponding to telomerase TERT. 
Adenovirusni hibridni vektor sa genskom ekspresijom prema patentnom zahtjevu 1, naznačen time što je element iii. tumor specifični promotor koji ima sekvencu izabranu od SEQ ID Neo 7, koja odgovara AFP p+e, i SEQ ID No 15, koja odgovara telomeraza TERT.
The pharmaceutical composition according to claim 11, wherein said arthritides and connective tissue disease is selected from the group consisting of reactive arthropathies, postinfective arthropathies, inflammatory polyarthropathies, systemic connective tissue disorders, inflammatory spondylopathies, myositis, synovitis, Reiter's disease, seropositive rheumatoid arthritis, rheumatoid arthritis, extraarticular rheumatoid disease, psoriatic and enteropathic arthropathies, juvenile arthritis, arthritis, polyarteritis nodosa and related conditions, necrotizing vasculopathies, dermatopolymyositis, systemic sclerosis, systemic involvement of connective tissue, ankylosing spondylitis and inflammatory spondylopathies. 
Farmaceutski pripravak za uporabu prema zahtjevu 18, gdje su spomenuti artritis i bolest vezivnog tkiva izabrani iz skupine koja se sastoji od reaktivnih artropatija, postinfektivnih artropatija, upalnih poliartropatija, sustavnih bolesti vezivnog tkiva, upalnih spondilopatija, miozitisa, sinovitisa, Reiterove bolesti, seropozitivnog reumatoidnog artritisa, reumatoidnog artritisa, ekstraartikularne reumatske bolesti, psorijatskih i enteropatskih artropatija, juvenilnog artritisa, artritisa, poliarteritisa nodoze i srodnih stanja, nekrotizirajućih vaskulopatija, dermatopolimiozitisa, sustavne skleroze, sustavnog zahvaćenja vezivnog tkiva, ankilozantnog spondilitisa i upalnih spondilopatija.
The reaction mixture is poured onto water (300 ml) and extracted with 1:1 ethyl acetate/diethyl ether. 
Reakcijsku smjesu se prelije na vodu (300 ml) 1 ekstrahira s 1:1 etil acetat/dietil eterom.
removing the protecting group from the salt having formula VII in the presence of a solvent to form a salt having Formula VIII wherein A- is an anion; and 
(i) uklanjanje zaštitne skupine sa soli koja ima formulu VII u prisutnosti otapala da bi se formirala sol koja ima formulu VIII o
Q is selected from the group consisting of phenyl, pyridyl, thiazolyl, thiophenyl, pyrimidyl, each optionally substituted with one or two groups independently selected from the group consisting of C1-6 alkyl, halogen or CF3; wherein 
Q je izabran iz grupe koju čine fenil, piridil, tiazolil, ttofenil, pirimidil, svaki izborno supstituiran sa jednom ili dvije grupe nezavisno izabrane 1z grupe koju čini Ci.g alkil, halogen ili CF;;
A process for producing box structures as claimed in claim 1, characterised by forming on the surface of the metal sheet a plurality of tangs (38) obtained by punching and bending portions of metal sheet. 
Postupak proizvodnje struktura u obliku kutije prema zahtjevu 1, naznačen time što se na površini metalne pločice oblikuje više zubaca (38) izbijanjem i savijanjem dijelova metalne pločice. t>&
The modified release pharmaceutical composition of claim 1, wherein the anionic non-cellulose-based water-swellable polymer is selected from the group consisting of anionic derivatives of agar; anionic derivatives of guar gum; anionic derivatives of locust bean gum; anionic derivatives of xanthan gum; anionic derivatives of alginin; anionic derivatives of polysaccharides of mannose and galactose, or chitosan; anionic derivatives of modified starch; and combinations thereof. 
Farmaceutski oblik s prilagođenim otpuštanjem prema zahtjevu 1, gdje se anionski polimer koji nije na bazi celuloze i koji bubri u vodi izabire iz grupe koja obuhvaća anionske derivate agara; anionske derivate guar gume; anionske derivate karuba gume; anionske derivate ksantan gume; anionske derivate alginina; anionske derivate polisaharida manoze i galaktoze, ili kitosana; anionske derivate modificiranog škroba i njihove kombinacije.
A yarn as claimed in claim 1 wherein the staple fibre length is from 30 to 60mm. 
Pređa u skladu s patentnim zahtjevom 1, naznačeno time, da pri čemu je dužina sortiranog vlakna od 30 do 60 mm.
The arm (1) according to claim 1, wherein said actuator (4) is contained within said support structure (21, 22, 23, 24, 25, 26). 
Ruka (1) u skladu sa prethodnim patentnim zahtjevom, gdje je spomenuti pokretač (4) sadržan unutar spomenute potporne strukture (21, 22, 23, 24, 25, 26).
In further aspects, the invention relates to a nucleic acid comprising a nucleotide sequence encoding the peptide of the invention and a cell comprising the nucleic acid. The nucleic acid may be a recombinant nucleic acid. 
Nukleinska kiselina koja sadrži nukleotidnu sekvencu koja kodira peptid sukladno patentnom zahtjevu 1 ili 2, naznačena time, da je nukleinska kiselina, poželjno, rekombinantna nukleinska kiselina.
A compound of formula (IB) according to claim 1, wherein is hydrogen or halogen; is hydrogen or halogen; 
Spoj formule (IB) prema patentnom zahtjevu 1, naznačen time, da R! je vodik ili halogen; R- je vodik ili halogen;
The compound for use in a method of treatment or the use according to any one of claims 14-16, wherein: 
Spoj za uporabu u postupku liječenja prema zahtjevu 11 ili uporaba prema zahtjevu 11, naznačen(a) time, da:
The use of claim 1, wherein the one or more additional compounds is a catechol-O-methyltransferase inhibiting compound selected from the group consisting of entacapone, tolcapone, nitecapone, and combinations thereof. 
Farmaceutski sastav, prema zahtjevu 20, naznačen je time da su u njemu inhibirajući spojevi katekol-O-metiltransferaze odabrani iz grupe koja se sastoji od entakapona, tolkapona, nitekapona i njihovih kombinacija.
A composition of matter comprising a protein according to SEQ ID No: 2 and/or 3. 
Pripravak tvari, naznačen time što sadrži protein u skladu sa SEQ ID No: 2 i/ili 3.
The use of a pharmaceutical composition of any preceding claim, for the manufacture of a medicament for the treatment of painful muscle spasms associated with static and functional disorders of vertebra or occurred in post-operations of osteoarthritis, pain and inflammatory symptoms associated with tissue trauma, degenerative vertebra diseases as torticollis, dorsalgy, lombalgy, disk hernia, neurologic and traumatic disorders associated with spasticity. 
Upotreba farmaceutskog pripravka prema bilo kojem od prethodnih zahtjeva, naznačen time što služi za proizvodnju lijeka za liječenje bolnih mišićnih grčeva povezanih sa statičkim 1 funkcionalnim poremećajima kralježnice ili prisutnih u periodu poslije operacija osteoartritisa, boli i simptoma upale povezanih s ozljedom tkiva, degenerativnih bolesti kralježnice kao što su tortikolija, dorzalgija, lumbalgija, hernia diska, neurološki i traumatološki poremećaji vezani uz spastičnost.
LDPC-decoding the Layer 1 signaling data and the de-punctured LDPC parity bit; and 
LDPC-dekodiranje signalnog podatka razine 1 i sabijenih LDPC paritetnih bitova; 1
Stevens-Johnson syndrome), seborrheic dermatitis, ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome, gout, chondrocalcinosis, joint pain secondary to dysmenorrhea, fibromyalgia, musculoskeletal pain, neuropathic-postoperative complications, polymyositis, acute nonspecific tenosynovitis, bursitis, epicondylitis, post-traumatic osteoarthritis, synovitis, and juvenile rheumatoid arthritis. 
StevensJohnsonov sindrom), seboreični dermatitis, ankilozantni spondilitis, psorijatični artritis, Reiterov sindrom, giht, hondrokalcinoze, bol u zglobovima uslijed dismenoreje, fibromialgija, muskuloskeletalna bol, neuropatske postoperativne komplikacije, polimiozitis, akutni nespecifični tenosinovitis, bursitis, epikondilitis, posttraumatski osteoartritis, sinovitis 1 juvenilni reumatoidni artritis, naznačen time, da se spoj primjenjuje transdermalno.
A method for producing a composition, comprising the step of mixing difluoromethane (R32), pentafluoroethane (R125), and 1,1,1,2-tetrafluoroethane (R134a) such that the composition ratio thereof is adjusted to fall within a triangle having the following three points as vertices in a ternary composition diagram in which the sum of the concentrations of R32, R125, and R134a is 100 wt%: 
Metoda proizvodnje sastava prema bilo kojem od zahtjeva 1 – 11, obuhvaćajući miješanje R32, R125, R134a na način da je njihov omjer u sastavu prilagođen da pada unutar raspona određenog u zahtjevu 1. Metoda upravljanja rashladnim uređajem, koja obuhvaća upravljanje rashladnim ciklusom korištenjem sastava iz bilo kojem od zahtjeva 1 – 11.
the additional therapeutic agent is at least one selected from glucocorticoids, cyclosporin, methotrexate, non-steroidal anti-inflammatory drugs (NSAIDs), TNF-a antagonists, IL-1 antagonists, IL-6 antagonists, and opioids; or 
(i) < dodatno terapeutsko sredstvo je najmanje jedno sredstvo odabrano iz grupe koja se sastoji od inzulina ili njegovih analoga, glukokortikosteroida, ciklosporina, metotreksata, nesteroidnih protuupalnih lijekova (NSAID), antagonista TNF-a, antagonista IL-1, antagonista IL-6 i opioida; i/ili
is hydrogen, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -C(=NH)NR4R5, -(CR10R11)pR25, or 
Q; je vodik, po izboru supstituirani aril, po izboru supstituirani aralkil, po izboru supstituirani cikloalkil, po izboru supstituirani cikloalkilalkil, po izboru supstituirani hetcrociklil, po izboru supstituirani heterociklilalkil, po izboru HR P20170154 T1
adding cold water, stirring the resultant biphasic mixture for 20 minutes at 0°C, and isolating the crude trans-(+)-A9-tetrahydrocannabinol from the organic phase; 
dodavanje hladne vode, miješanje nastale dvofazne smjese tokom 20 minuta na 0°C, te izoliranje sirovog trans-(+)-A9-tertahidrokanabinola iz organske faze;
A nasal spray device as claimed in any preceding claim, wherein a maximum transverse dimension of the transfer channel (13) is from 1.2 to 2 mm, preferably about 1.5 mm. 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu je maksimalna transverzalna dimenzija prijenosnog kanala (13) od 1.0 do 3.0 mm.
The compound or single isomer or tautomer thereof of Claim 1, where the cancer is selected from breast cancer, colon cancer, rectal cancer, endometrial cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, glioblastoma, hepatocellular carcinoma, small cell lung cancer, non-small cell lung cancer, melanoma, ovarian cancer, cervical cancer, pancreatic cancer, prostate carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, and thyroid carcinoma. 
Spojili njegov pojedinačni izomer ili tautomer prema patentnom zahtjevu 1, naznačen time što je kancer izabran iz grupe koju čine kancer dojke, kancer debelog crijeva, kancer rektuma, kancer endometrija, gastrointestinalni karcinoidni tumori, gastrointestinalni stromalni tumori, glioblastom, hepatostanični karcinom, sitnostanični kancer pluća, nesitnostanični kancer pluća, melanom, kancer jajnika, kancer grlića materice, kancer pankreasa, karcinom prostate, akutna mijelogena leukemija, kronična mijelogena leukemija, ne-Hodgkinov limfom i karcinom tireoidee.
The separation element 1 may be a discrete element, or it may be attached to or integral with one of body 2 and cover 4. 
Uređaj prema jednom od patentnih zahtjeva 1 do 8, pri čemu je element (1) odvajanja integralan sa najmanje jednim od tijela i poklopcem.
guide strands A short hairpin RNA molecule (shRNA) comprising 
Molekula kratke RNA-ukosnice (sShRNA - short hairpin RNA), naznačena time, da obuhvaća:
hydrogen, substituted and unsubstituted alkyl, and 
(5) supstituirani i nesupstituirani alkil,
The resultant solution was stirred for 20 hr, and acetonitrile was removed in vacuo. 
Dobivenu otopinu miješa se 20 sati, a acetonitril ukloni u vakuumu.
The overpressure may for example be of about 300 millibars. 
Tlak primjerice može biti u vrijednosti od oko 300 milibara.
A compound of Formula (Ia), wherein: 
Spoj formulo (Ta), naznačen time da:
administering to the mammal a therapeutically effective amount of a compound of Formula (I): 
HR P20180746 T1 PATENTNI ZAHTJEVI mne» Spoj s formulom (I):
A method of producing electric power by providing a floating body to float on the sea, providing an electric linear generator having a stator and a translator reciprocating along a center axis, anchoring the stator in the bed of the sea and connecting the translator to the floating body by connection, means, enclosing the generator, in a water-tight encapsulation, arranging the connection means to extend through an opening in an upper end wall of the encapsulation, sealing the connections means that passes through the opening and mounting the sealing flexible in order to allow axial movement of the seal with respect to the upper end of the wall. 
Postupak proizvodnje električne energije osiguravanjem plutajućeg tijela, koje omogućuje plutanje na moru, osiguravanjem linearnog električnog generatora koji ima stator i translator, koji oscilira po središnjoj osi, sidrenjem statora u morsko dno i spajanjem translatora s plutajućim tijelom spojnim elementom, oklapanjem generatora u vodonepropusnu kapsulu, osiguravanjem pružanja spojnog elementa kroz otvor u stijenci na gornjem kraju kapsule, brtvljenje spojnog elementa koji prolazi kroz otvor i montiranjem fleksibilne brtve, naznačen time što je kapsula napunjena plinom pod pretlakom.
The method of claims 1-6, wherein the saccharide is a bacterial capsular saccharide, for instance derived from a bacterium selected from a list consisting of: N. meningitidis serogroup A, B, C, W135 or Y, Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F or 33F, Group B Streptococcus group la, Ib, II, III, IV, V, VI, or VII, Staphylococcus aureus type 5, Staphylococcus aureus type 8, Salmonella typhi (Vi saccharide), Vibrio cholerae, or H. influenzae type b. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sadrži vezikularni pripravak vanjske membrane bakterije N. meningitidis seroskupina B. Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije S. pneumoniae kojeg se dobiva iz soja kojeg se bira iz skupine koju čine serotipovi 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F i 33F.
A compound selected from the group consisting of: 
Spoj prema zahtjevu 1 odabran iz skupine koja se sastoji od:
a 0.9 % solution of sodium chloride; a 0.45 % or 0.225 % solution of sodium chloride; and Ringer's solution and/or Ringer's lactate solution; wherein said composition has preferably a pH value of 5 to 8, preferably of 6.0 to 7.5 . 
0,9%-tne otopine natrijevog klorida; 0,45%-tne ili 0,225%-tne otopine natrijevog klorida; te Ringer-ove otopine i/ili Ringer-ove laktatne otopine; pri čemu spomenuti sastav ima pH vrijednost poželjno od 5 do 8, još bolje od 6,0 do 7,5.
The gun stock according to claim 1, characterized in that said leaf spring comprises an elastic blade, said blade having a first end that can be inserted in a seat formed in said cheek rest structure, and a second end that is adapted to abut against an abutment member formed in said structure in a position that is opposite to the position of said seat. 
Kundak u skladu s patentnim zahtjevom 1, naznačen time što navedena listasta opruga sadrži elastični list, gdje navedeni list ima prvi kraj (51), kojeg se može umetnuti u sjedište (6), načinjeno u navedenoj strukturi naslona za obraz, i drugi kraj (52), prilagođen za oslanjanje na potporni element (7), načinjen u navedenoj strukturi u položaju koji je nasuprot položaju navedenog sjedišta.
A composition for use according to claim 9 wherein the patient has a rate of urine production during sleep that is greater than the patient's overall average daily rate of urine production; and/or wherein the patient is over 65 years of age with a serum sodium level of at least 135 after administration. 
Pripravak za uporabu prema zahtjevu 8, naznačen time da pacijent ima stopu proizvodnje urina tijekom spavanja veću od stope cjelodnevne proizvodnje urina pacijenta; i/ili pri čemu je pacijent stariji od 65 godina s razinom natrija u serumu, nakon administracije, od barem 135.
A process for the preparation of a compound of formula (VI), which comprises hydrolysis and decarboxylation of a compound of formula (VII) wherein R1, R2, and Q are as defined in claim 12 and P is a suitable alkyl group. 
(VID) i haa N OP 07"op (VII) gdje su R!, R* i Q definirani kao u patentnom zahtjevu 12, a P je pogodna alkilna skupina.
wherein said patient maintains a DRL corresponding to consumption >60 g/day of pure alcohol for men and >40 g/day for women after an observation period following initial assessment, assessed by calculating mean daily alcohol consumption in g/day over said observation period; 
gdje se taj DRL održavanja procjenjuje računanjem srednje dnevne konzumacije alkohola u g/dan kroz navedeni period promatranja; i gdje se nalmefen daje u terapijski učinkovitoj količini; i gdje se nalmefen daje po potrebi, kao svaki dan kada bolesnik osjeti da postoji rizik da pije alkohol, poželjno 1-2 sata prije očekivanog vremena pijenja.
▪ R1 represents a (C1-C6)alkyl group; ▪ R2 and R3 represent, independently of each other, a hydrogen atom or a (C1-C6)alkyl group; or alternatively R2 and R3 form together with the carbon atom to which they are attached a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group; 
: Ri predstavlja skupinu (C;-Cg)alkil; " R,iR; predstavljaju, neovisno jedan od drugoga, vodikov atom ili skupinu (C;-Cg)alkil; ili alternativno R2 i Rz tvore zajedno s ugljikovim atomom na koji su oni vezani skupinu (C3-Cg)cikloalkil ili skupinu (C3-Cg)heterocikloalkil;
providing a nucleic acid sample from cancer cells from a patient that has a cancer; 
- < dobavljanje uzorka nukleinske kiseline iz stanica raka od pacijenta koji ima rak;
After this time, perfusion was stopped. 
Nakon toga je perfuzija zaustavljena.
<400> 6 A pharmaceutical composition comprising a ROBO2 inhibitor that inhibits ROBO2 biological activity, wherein the ROBO2 inhibitor is a soluble ROBO2 protein comprising a fusion polypeptide comprising both the Ig1 and Ig2 SLIT binding domains of ROBO2 with no intracellular ROBO2 domain. 
PATENTNI ZAHTJEVI 1. - Farmaceutski pripravak koji sadrži inhibitor ROBO2 koji inhibira ROBO2 biološku aktivnost, naznačen time što je inhibitor ROBO2 topljivi protein ROBO2 koji sadrži fuzijski polipeptid koji sadrži domene za vezanje i na Ig1 SLIT i na Ig2 SLIT u ROBOZ2, bez unutarstanične domene ROBO2.
A method of inhibiting the growth of the cell expressing a human CD38 protein (SEQ ID NO: 1) by contacting said cell with an antibody, wherein said antibody specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 SEQ ID NO:2) and comprises: a heavy chain variable region comprising: 
Izolirano protutijelo koje specifično veže ljudski CD38 (SEQ ID NO: 1) 1 makaki CD38 (SEQ ID NO:2) koje sadrži: a) = varijabilnu regiju teškog lanca koja sadrži SEQ ID NO:9; 1 b) varijabilnu regiju lakog lanca koja sadrži SEQ ID NO:10.
is an acidic amino acid; is a basic amino acid; is selected from the group consisting of Leu, Ile, Val, Met, Trp, Tyr and Phe; and 
€) x3ili Xxx, se pojedinačno i neovisno bira iz skupine koju čine Leu, Ile, Val, Met, Trp, Tyr i Phe; iili d) xaili Xxx4 se pojedinačno i neovisno bira iz skupine koju čine Ser, Thr, Ala i Gly.
The compound for use of claim 1, wherein the compound of formula Ia or the salt thereof is administered sequentially with the one or more agents. 
Spoj u kombinaciji za uporabu prema zahtjevu 1, naznačen time, da je spoj formule Ia namijenjen za uzastopnu primjenu s abirateronom.
injecting gas into the pretreated sewn ball obtained by the step (5) to form a round ball, putting the round ball into a reshaping mould, pressurizing and reshaping with a pressure of 3-10 kg/cm2, a time of 1-8 min, and a mould temperature of 30-70 °C for attaching the housing to the surface of the inner tube (5), and cleaning a surface of the housing (4), thereby obtaining the sewn ball, wherein a circumferential error of the reshaped sewn ball is less than 2 mm. 
(6) injektiranje plina u predobrađenu zašivenu loptu koja je dobivena u koraku (5) u svrhu oblikovanja okrugle lopte, stavljanje okrugle lopte u kalup za ponovno oblikovanje, tlačenje 1 ponovno oblikovanje s tlakom od 3 do 10 kg/cm', u vremenu od 1 do 8 min, i na temperaturi kalupa od 30 do 70%C, za pričvršćivanje omotača na površinu unutrašnjeg balona (5), te čišćenje površine omotača (4), a time dobivanje zašivene lopte, pri čemu je pogreška obujma ponovno oblikovane zašivene lopte manja od 2 mm.
Since these devices protect the electrical system of a house as a whole, their sensibility is limited to 30mA, not to take into account small parasitic leakage currents naturally flowing in a system. 
S obzirom da ovi uređaji služe zaštiti električkog sustava (kuće) domaćinstva kao cjeline, njihova osjetljivost je ograničena na 30 mA, ne uzimajući u obzir male parazitne struje odvoda koje normalno teku u sustavu.
The receiver of claim 5, wherein the Layer 1 signaling data has Program Specific Information(PSI) and Service Information(SI) reprocessing information for each Physical Layer Pipe (PLP), and the PSI/SI reprocessing information indicates whether or not a PSI/SI reprocessing has been performed. 
Prijamnik iz patentnog zahtjeva 5, gdje signalni podaci Razine 1 imaju programski specifičnu informaciju (PSI) 1 servisnu informaciju (SI) ponovo obrađuju informaciju za svaku cijev fizičke razine (PLP), i ponovna obrada PSI/SI informacija ukazuje je li ili nije provedena ponovna obrada PSISI.
A process for preparing a compound according to claim 1 which comprises reacting a compound of formula (V) 
Postupak pripreme spoja prema patentnom zahtjevu 1, naznačen time da sadrži reakciju spoja formule (V) o o,
The crystallized pellets were subjected to a microscopic analysis, the result of which is shown in FIG. 2 . 
Iz kristaliziranih je peleta također napravljena mikroskopska analiza prikazana na Slici 2.
The organic-inorganic composite of para. 1, wherein the substituted starch is hydroxyethylated, hydroxypropylated, or acetylated. 
Zidna gips ploča prema zahtjevu 1, naznačena time, da supstituirani škrob je hidroksietiliran, hidroksipropiliran ili acetiliran.
is a heterocyclic ring selected from the group consisting of indolediyl groups and indolinediyl groups, wherein the heterocyclic ring may have at least one substituent: 
Au je heterociklički prsten odabran iz skupine koju čine indoldiil skupine 1 indolindiil skupine, gdje heterociklički prsten može imati najmanje jedan supstituent;
Preference is given to compounds of the formula (I) in which represents C1-C6-alkyl, where alkyl is substituted by 1 to 2 substituents independently of one another selected from the group consisting of hydroxy, C1-C4-alkoxy and cycloalkyloxy and R2 represents hydrogen or C1-C4-alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a 4- to 7-membered N-heterocycle, 
R! i R* zajedno s dušikovim atomom na koji su oni vezani tvore 4- do 7-člani N-heterocikl, gdje N-heterocikl može biti supstituiran s 1 do 3 supstituenta koji su međusobno neovisno odabrani iz skupine koja sadrži okso, hidroksi, monofluorometil, difluorometil, -trifluorometil, -hidroksikarbonil, tertbutoksikarbonil, aminokarbonil, C;-Ca-alkil, C1-C4-alkoksi i halogen, ili gdje N-heterocikl može imati dva supstituenta koji, zajedno s ugljikovim atomom iz N-heterocikla na koji su oni zajednički vezani, tvore 4- do 6-člani heterocikil, gdje ovaj heterocikl sa svoje strane može biti supstituiran s 1 do 3 supstituenta koji su međusobno neovisno odabrani iz skupine koja sadrži okso, metil i etil,